Viridian Therapeutics, Inc. VRDN Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -543.9%+111,047pp | -512.9%+98,506pp | -463.5%+93,259pp | -121,831.1%-34,753pp | -111,591.1%-28,996pp | |
| Net margin | -508.5%+101,584pp | -483.6%+88,904pp | -426.6%+84,701pp | -112,806.9%-33,621pp | -102,092.4%-26,355pp | |
| EBITDA margin | -543.2%+110,878pp | -512.3%+98,327pp | -462.9%+93,072pp | -121,672.8%-34,793pp | -111,421.5%-29,022pp | |
| Free cash flow margin | -428.4%+92,401pp | -390.8%+76,705pp | -461%+64,914pp | -101,507.9%-42,890pp | -92,829.8%-34,426pp | |
| Returns | ||||||
| Return on equity | -58.1%-6.2pp | -49.2%-0.7pp | -49.9%+2.0pp | -65.9%-11.9pp | -51.9%-5.2pp | |
| Return on assets | -49.7%-2.0pp | -41.7%+2.1pp | -44.8%+1.9pp | -58.9%-10.2pp | -47.8%-4.9pp | |
| Return on invested capital | -76.5%-10.7pp | -64.8%-0.9pp | -73.9%+4.2pp | -85.9%-12.1pp | -65.8%-4.9pp | |
| Efficiency | ||||||
| Asset turnover | 0.1×+0.1× | 0.1×+0.1× | 0.1×+0.1× | 0×0.0× | 0×0.0× | |
| Liquidity | ||||||
| Current ratio | 15.1×-4.3× | 12.6×-2.8× | 11.3×-7.3× | 11×-4.8× | 19.5×-4.5× | |
| Quick ratio | 15.1×-4.3× | 12.6×-2.8× | 11.3×-7.3× | 11×-4.8× | 19.5×-4.5× | |
| Cash ratio | 3.4×0.0× | 3×+0.9× | 3.3×-1.5× | 2.2×-0.7× | 3.4×-0.1× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0.1×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Interest coverage | -49.3×+104× | -74.1×+60.0× | -153.3×-19.3× | -176.1×-61.3× | -153.7×-18.0× | |
| Valuation | ||||||
| Market capitalization | $2B+82.0% | $2.97B+95.6% | $1.76B+1.4% | $1.2B+44.1% | $1.1B-0.1% | |
| Enterprise value | $1.86B+85.0% | $2.79B+96.6% | $1.62B+3.6% | $1.1B+47.9% | $1.01B-2.3% | |
| Price / sales | 28.2×-3,609× | 41.9×-4,986× | 24.9×-5,727× | 3,921.8×+1,039× | 3,637.1×-179× | |
| Price / book | 3.1×+1.3× | 4.1×+1.9× | 3.5×+1.0× | 2.3×+0.8× | 1.8×-0.1× | |
| EV / sales | 26.2×-3,303× | 39.4×-4,667× | 22.8×-5,143× | 3,612.8×+1,025× | 3,328.8×-245× | |
| Free cash flow yield | -15.2%+10.3pp | -9.3%+6.0pp | -18.5%-7.2pp | -25.9%-5.6pp | -25.5%-10.2pp | |
| Earnings yield | -18%+10.0pp | -11.5%+6.2pp | -17.1%-2.3pp | -28.8%-1.3pp | -28.1%-8.2pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Viridian Therapeutics, Inc.'s profit margins?
- Viridian Therapeutics, Inc. (VRDN) runs a 36.3% gross margin and a -543.9% operating margin, with a -508.5% net margin.
- Where do Viridian Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Viridian Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.